Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-24-050627
Filing Date
2024-12-10
Accepted
2024-12-10 16:51:44
Documents
3
Period of Report
2024-12-10

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1733867495.html 3  
1 FORM 3 wk-form3_1733867495.xml 3 1617
2 EX-24.EX-24.POADAVIS davismark-powerofattorne.htm EX-24.EX-24.POADAVIS 4357
3 GRAPHIC davismark-powerofattorne001.jpg GRAPHIC 238951
  Complete submission text file 0001628280-24-050627.txt   336630
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Issuer) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O YEXT, INC. 61 NINTH STREET NEW YORK NY 10011
Business Address
Davis Mark Steven (Reporting) CIK: 0002024613 (see all company filings)

Type: 3 | Act: 34 | File No.: 000-26642 | Film No.: 241539165